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ABSTRACT
Vulvovaginal candidiasis (VVC) is one of the most frequent infections affecting women worldwide. Healthy vaginal
microbiota is dominated by lactobacilli, which form a strong defense line against pathogens. In this work, in vitro
antimicrobial properties of thirty vaginal Lactobacillus strains were evaluated against eleven Candida vaginal clinical isolates,
employing three different methods. Also, the effect of intravaginal (i.va.) administrations (preventive, therapeutic and
preventive-therapeutic) of L. reuteri CRL1324 or L. rhamnosus CRL1332 strains against the i.va. challenge with Candida albicans
(C.a.) was evaluated in a murine experimental model. From the results of agar overlay and liquid medium assays the
selected lactobacilli strains have shown to inhibit the growth of at least one Candida strain. The inhibition was mainly due
to the effect of organic acids. Anti-Candida activity was not evidenced in the agar plate diffusion method. In the
experimental murine model, only preventive-therapeutic administration of both lactobacilli was able to significantly reduce
viable C.a. numbers recovered in vaginal washes and the leukocyte influx induced by the fungi. In conclusion, lactobacilli
exhibited in vitro and in vivo antimicrobial effects on Candida, suggesting that they could be promising candidates for
protection against VVC. Lactobacilli predominant in human vagina and protect from VVC. The manuscript reports different
methods to determine lactobacilli inhibitory effect at the laboratory, and protection against Candida in murine vagina.
Keywords: Candida spp.; beneficial lactobacilli; murine model; vulvovaginal candidiasis; in vitro and in vivo studies;
anti-Candida activity
INTRODUCTION
Vulvovaginal candidiasis (VVC) is a high-incidence disease
affecting the life quality of women worldwide. Around 75% of all
women of reproductive age suffer from VVC at least once during
their lifetime, with approximately 5% to 8% experiencing up to
four or more episodes per year (Peters et al. 2014; Cassone 2015).
The most frequent etiologic agent is the opportunistic pathogen
Candida albicans, the fungal species with highest prevalence in
the human microbiota (Workowski and Berman 2010; da Silva
Dantas et al. 2016). However, other varieties of Candida species
such as C. glabrata, C. krusei and C. tropicalis are associated with
VVC (Mahmoudi Rad et al. 2011). It has been suggested that
the overgrowth of Candida spp. is facilitated by the disruption
of the microbial vaginal balance. Factors increasing the risk for
the development of VVC are antibiotic therapies, pregnancy sta-
tus, genetic polymorphisms and susceptibility, use of contracep-
tives and/or spermicides, sexual intercourse, immunosuppres-
sion and diabetes (Babula et al. 2005; Sobel 2007; Sangaré et al.
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2017). The therapy usually applied against VVC consisted in the
use of antifungal azoles. However, these drugs are fungistatic
for C. albicans, and prolonged exposition can generate high pres-
sure, thus promoting the appearance of azole-resistant Candida
(Coste et al. 2007). In this way, recurrent VVC is a serious clinical
condition due to the lack of successful therapies. Long-term flu-
conazole treatment can promote longer asymptomatic periods
between recurrences, but does not provide a definitive cure. This
fact leads to a low quality of life together with high expenses
associated with medical visits and therapies (Marchaim et al.
2012; Foxman et al. 2013; Sobel 2015). Therefore, novel antifun-
gal drugs or successful alternative therapies for VVC are urgently
required.
Lactobacilli are the predominant microorganisms in the vagi-
nal microbiome of healthy women, preventing the overgrowth
of opportunist microorganisms and pathogens (Nader-Macı́as
and Juárez Tomás 2015; Mendling 2016). Recent studies on the
human microbiome showed that different species of Lactobacil-
lus including Lactobacillus iners, L. crispatus, L. gasseri, L. jensenii,
and to a lesser extent, L. acidophilus, L. fermentum, L. plantarum,
L. brevis, L. delbrueckii, L. salivarius, L. reuteri, L. casei, L. vagi-
nalis and L. rhamnosus (Ravel et al. 2011; Douillard and de Vos
2014) are host-specific, dominant and exclusive in the human
vagina (Human Microbiome Project Consortium 2012; Integra-
tive HMP (iHMP) Research Network Consortium 2014). However,
the species present depend on ethnic background, genetic poly-
morphism, environmental and behavioral factors (Yildirim et al.
2014; Mendling 2016). The universality and host-specificity of
vaginal Lactobacillus species are the support for novel therapeu-
tic opportunities for the treatment of alterations in the vaginal
microbiome (Reid 2017).
Lactobacilli can exert their function through different mech-
anisms, including a) biofilm formation on the vaginal mucosa, a
phenomenon affected both by the production of biosurfactants
and by the capability of these bacteria for self- or coaggregation;
b) adhesion to epithelial cells, mucus and/or extracellular matrix
components; c) production of antimicrobial substances (organic
acids, hydrogen peroxide, bacteriocins); d) enzyme release (e.g.
arginine deaminase) competing for nutrients or e) modulation
of the immune system (Leccese Terraf et al. 2012; De Gregorio et
al., 2014, 2015; Leccese Terraf et al. 2014; Nader-Macı́as and Juárez
Tomás 2015; De Gregorio, Juárez Tomás and Nader-Macı́as 2016;
Reid 2016; Leccese Terraf et al. 2017). In vitro and in vivo stud-
ies are required to demonstrate the beneficial effect of different
Lactobacillus strains because the effect is strain-specific (De Gre-
gorio et al. 2012; De Gregorio et al. 2014). Thus, the aims of this
study were to: a) evaluate the in vitro antimicrobial properties
of 30 different vaginal Lactobacillus strains, previously selected
for their beneficial properties, against 11 vaginal clinical isolates
of Candida spp. through different methodologies, and b) deter-
mine the effect of intravaginal (i.va.) administration (preventive,
therapeutic and preventive-therapeutic protocols) of Lactobacil-
lus strains against the i.va. challenge with C. albicans in a murine
experimental model.
METHODS
Microorganisms and culture conditions
Thirty Lactobacillus strains from the Centro de Referencia para
Lactobacilos Culture Collection (CRL, Tucumán, Argentina), orig-
inally isolated from healthy (without infection) and unhealthy
(with infection) human vagina (Ocaña et al. 1999), and selected
for their beneficial properties (Ocaña, Pesce de Ruiz Holgado and
Nader-Macı́as 1999; Vera Pingitore et al. 2009; Juárez Tomás et al.
2011; Leccese Terraf et al. 2012; De Gregorio et al., 2014, 2015;
Leccese Terraf et al. 2014; De Gregorio, Juárez Tomás and Nader-
Macı́as 2016; Leccese Terraf et al. 2017) were evaluated in this
work. The Lactobacillus strains used and the health status of the
vaginas from which the strains were originally isolated are sum-
marized in Table 1. All the strains were grown in microaerophilic
conditions in De Man-Rogosa-Sharpe (MRS) broth (Biokar Diag-
nostics, France) (De Man, Rogosa and Sharpe 1960) at 37◦C for 24
h and subcultured twice in the same medium at 37◦C for 12 h
before use.
Eleven vaginal clinical isolates of Candida sp. were kindly pro-
vided by Dr. Virginia Ocaña from the Nuevo Hospital ‘El Mila-
gro’ (Salta, Argentina) (codified as F11 and F18), Dr. Cristina Gau-
dioso de Allori from the Acción Social Universidad Nacional de
Tucumán (ASUNT, Tucumán, Argentina) (codified as C1 and C2)
and Biochemist Cecilia Vallejo from the Universidad Nacional
de Tucumán (codified as HE2, HE3, HE4, HE5, HE6, HE7 and
HE10). Candida strains were grown aerobically for 16 h at 37◦C
in Sabouraud dextrose (SD) medium [% (w/v): 40 glucose and 10
peptone, pH 5.6; Britania Laboratories, Argentina].
All microorganisms were stored in milk-yeast extract [%
(w/v): 13 nonfat milk, 0.5 yeast extract and 1 glucose; Britania
Laboratories, Argentina] with 20% glycerol (Cicarelli Laborato-
ries, Argentina) at −20◦C.
Identification of Candida sp. vaginal clinical isolates
For the identification of Candida sp. vaginal clinical isolates
at the species level, saline suspensions (previously grown in
SD broth) were cultured in CHROMagar Candida R© (CHROMagar
Company, France) plates for 24 to 48 h at 35◦C. The use of a
chromogenic medium contributes to the presumptive identifica-
tion of C. albicans, C. tropicalis and C. krusei (Odds and Bernaerts
1994) and allows working with re-isolated colonies. Then, the
strains grown in the chromogenic medium were subcultured in
SD agar for 24 h at 37◦C, identification at the species level being
performed by matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS). This technique
allows the identification of the pathogens by generating a pro-
tein spectrum or ‘fingerprint’ that is unique for a given species
(Buchan and Ledeboer 2013; Clark et al. 2013). For the protein
extraction, a colony of each isolate was added in duplicate to a
96-well metallic plate (Bruker Daltonics, Germany) and allowed
to dry at room temperature. Then, 1 μL of formic acid (100%)
(Sigma-Aldrich, Argentina) and 1 μL of HCCA matrix (saturated
solution of α-cyano-4-hydroxycinnamic acid in 50% acetoni-
trile, 2.5% trifluoroacetic acid; Bruker Daltonics, Germany) were
added. Readings were performed in a Microflex LT mass spec-
trometer using the Flex Control software (version 3.0, Bruker
Daltonics, Germany). The spectrometer was calibrated using a
protein extract of Escherichia coli (Bruker Bacterial Test Standard).
The spectra obtained were compared with two databases simul-
taneously and the results were presented as a score (Clark et al.
2013). The following identification criteria were used according
to the manufacturer’s recommendations: a log score value ≥2
indicated correct identification at the species level, a value
between 1.7 and 1.9 indicated identification at the genus level
and a value <1.7 indicated lack of identification. The correct
identification of each isolate at the species-level was accepted
if at least one of the obtained duplicates scored >2.
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Qualitative determination of H2O2 production by
lactobacilli
Hydrogen peroxide production by Lactobacillus strains was deter-
mined by the chromogenic method in MRS agar medium plates
supplemented with tetramethyl-bencydine and horseradish
peroxidase, as described by Juárez Tomás et al. (2004). Briefly,
the plates were inoculated with the lactobacilli and incubated at
37◦C for 48 h under microaerophilic conditions. H2O2-producing
strains evidenced blue colonies after exposure to air for 30 min.
H2O2 production was classified as strong (score 2), moderate
(score 1) or negative (score 0) taking into account the intensity
of the blue color of the colonies.
In vitro anti-Candida activity of lactobacilli
Antimicrobial activity of Lactobacillus strains
The antimicrobial effect of vaginal lactobacilli against Candida
spp. was evaluated with the agar overlay technique with minor
modifications (do Carmo et al. 2016). Briefly, MRS agar plates
were inoculated with 10 μL of Lactobacillus suspensions (108 UFC
mL−1) and incubated at 37◦C for 24 h under microaerophilic con-
ditions. After incubation, 106 CFU Candida in 10 mL of melted
SD agar were added over the MRS containing the grown lacto-
bacilli. The plates were again incubated aerobically at 37◦C for 24
h to allow Candida growth. Inhibition zones over or around Lacto-
bacillus colonies indicated antimicrobial activity. The diameters
of the inhibition halo were calculated by subtracting the colony
diameter from the total diameter. Three independent experi-
ments were performed.
Antimicrobial activity of cell free supernatant from Lactobacillus
strains
Cell free supernatant (CFS) was obtained by centrifugation of
the third Lactobacillus sub-culture (grown in MRS broth for 12 h
at 37◦C as described above in the microorganisms and culture
conditions section) at 6000 g for 10 min and sterilized through a
0.22 μm filter (Millipore, USA). CFS pH was determined by digital
pH meter (Sartorius AG, Germany). The effect of CFS on Candida
growth was evaluated in both solid and liquid medium assays.
For the solid medium assay, CFS (25 μl) was added to 4 mm
holes performed in the SD agar plates (1% agar) containing the
Candida strains (∼106 CFU). The plates were incubated for 4 h
at room temperature and then for 24 h at 37◦C. The inhibition
of Candida growth by CFS was evidenced by an inhibitory area
around the well. Two independent experiments were performed.
The CFS effect in liquid medium was performed in a 96-well
microplate assay according to Wang et al. (2017) with modifica-
tions. 100 μl containing approximately 2 × 105 CFU Candida in SD
medium were combined with 100 μl CFS in each well of sterile
microplates. As a control, MRS broth was used instead of CFS.
Moreover, MRS broth adjusted to pH 4.0 with HCl was included
to evaluate the effect of low pH on Candida growth. After aerobic
incubation at 37◦C for 24 h, fungus growth was determined by
optical density (OD) at 630 nm using a Microplate Spectropho-
tometer (VERSAmax, Molecular Devices, Sunnyvale, CA, USA).
Later, the growth inhibition rate was calculated as:
Growth inhibition rate (%) = [(ODcontrol−ODCFS) /ODcontrol] × 100
Each CFS was assayed in three independent experiments,
each with three replicates.
On the other hand, the inhibition assay in liquid medium
against C. albicans C2 was carried out again employing CFS neu-
tralized with 2 N NaOH, and neutralized-treated with 1000 U
mL−1 catalase (Sigma, USA) CFS in order to indicate the chemical
nature of inhibitory substances (organic acid and/or H2O2).
In vivo anti-Candida activity of lactobacilli
An experimental murine model was used to evaluate the
preventive, therapeutic and preventive-therapeutic effect of
the intravaginal (i.va.) inoculation of L. reuteri CRL1324 or L.
rhamnosus CRL1332 on the i.va. challenge with C. albicans C2.
These strains were selected considering several characteristics
explained below.
Animals
Two-month-old female BALB/c mice from the inbred colony of
CERELA (Centro de Referencia para Lactobacilos) were used. Ani-
mals were housed and fed as previously described (De Gregorio
et al. 2015). In order to induce a pseudo-estrous condition and
promote microbial colonization, the mice received a weekly sub-
cutaneous injection of 0.02 mg b-Estradiol 17-valerate (Sigma-
Life Sciences, Switzerland) dissolved in 100 μl of sesame oil
(Sigma-Life Sciences, Mexico) throughout the experiment. The
experiments were independently repeated three times (with at
least three animals) for each experimental group and sampling
time. The Institutional Laboratory Animal Care and Use Com-
mittee of CERELA approved the experimental CRL-BIOT-LMP-
2011/1A protocol applied in this work.
Mice were randomly assigned to seven experimental groups:
(1) one Control group: C. albicans C2 (C.a.)-challenged mice [i.va.
inoculated with saline twice a day for 4 days (a total of 7
times), later i.va. challenged with 20 μL containing 1 × 106
CFU C.a., and again i.va. inoculated seven times with saline
(one per day for 7 days)];
(2) two Preventive groups: Lactobacillus (Lb) (7 doses) + C.a.
treated-mice (i.va. inoculated seven times with 108 CFU L.
reuteri CRL1324 or L. rhamnosus CRL1332, later i.va. chal-
lenged with 1 × 106 CFU C.a., and i.va. inoculated seven
times with saline);
(3) two Therapeutic groups: C.a. + Lb (7 doses)-treated mice
(i.va. inoculated seven times with saline, later i.va. chal-
lenged with 1 × 106 CFU C.a., and i.va. inoculated seven
times with 108 CFU L. reuteri CRL1324 or L. rhamnosus
CRL1332) and
(4) two Preventive-Therapeutic groups: Lb (7 doses) + C.a. + Lb
(7 doses)-treated mice (i.va. inoculated seven times with 108
CFU L. reuteri CRL1324 or L. rhamnosus CRL1332, later i.va.
challenged with 1 × 106 CFU C.a., and i.va. inoculated seven
more times with 108 CFU L. reuteri CRL1324 or L. rhamnosus
CRL1332).
Lactobacillus inoculum was prepared from the cell pellet of
the third subculture (grown in MRS broth for 12 h at 37◦C as
described above) resuspended in 50 μl of melted agarized pep-
tone (% (w/v): 1 meat peptone, 1.5 agar; Britania Laboratories,
Argentina), as previously published (De Gregorio et al. 2015). C.
albicans C2 inoculum were suspensions of bacterial pellets from
cultures (in SD broth for 16 h at 37◦C, agitated at 70 rpm) washed
and resuspended in saline.
The experimental groups, the i.va. inoculation sequence and
the sampling days of the experiments are schematized in Fig. 1.
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Figure 1. Experimental design. H: Administration of 0.02 mg β-Estradiol 17-valerate (). The arrow shows one intravaginal (i.va.) inoculation of: saline (S,), lactobacilli [50
μL containing 108 CFU of L. reuteri CRL1324 or L. rhamnosus CRL1332 (Lb,)], or C. albicans C2 [20 μL containing around 106 CFU (C.a.,)] into BALB/c mice in the following
experimental groups: control, preventive, therapeutic and preventive-therapeutic. Sd (): Sampling day.
Sampling and analytical procedures
Every sampling day, vaginal washings (v.w.) and vaginal tissues
were obtained as previously described (De Gregorio et al. 2015).
Vaginal washing cytology and vaginal tissue histology were
carried out with May–Grünwald–Giemsa and Hematoxylin–
Eosin stains, respectively, according to De Gregorio et al. (2015).
Microbiological studies were performed from v.w. in which
Lactobacillus and Candida viable cell counts were determined by
serial dilution method in agar plates. MRS (pH 5.5) with 0.1 mg
mL−1 of cycloheximide (Sigma, China) was employed to selec-
tively quantify L. reuteri CRL1324 or L. rhamnosus CRL1332 and
Sabouraud glucose agar containing 0.05 mg L−1 chlorampheni-
col (Britania, Argentina) to quantify C. albicans C2. MRS plates
were incubated under microaerophilic conditions at 37◦C for 48
h, while Sabouraud plates were aerobically incubated at 37◦C for
24 h. The culture-based technique applied to evaluate L. reuteri
CRL1324, L. rhamnosus CRL 1332 and C. albicans C2 colonization
is supported by a previous study of our groups in which no lac-
tobacilli and yeast were isolated from vaginal autochthonous
microbiota of BALB/c mice in the culture media used (De Gre-
gorio et al. 2018).
Statistical analysis
For the in vitro anti-Candida activity assays, an analysis of vari-
ance (ANOVA) using a general linear model was applied to deter-
mine the main and interaction effects of factors (Lactobacillus
CFS and Candida strains) on Candida growth. For in vivo studies,
ANOVA using a general linear model was also applied to define
the main and interaction effects of factors (experimental group
and sampling day) on the number of viable C. albicans C2 and lac-
tobacilli. Significant differences (P-value < 0.05) between mean
values were determined by Tukey’s test, using MINITAB statisti-
cal software (version 16 for Windows).
RESULTS
Identification of Candida sp. vaginal clinical isolates
The results showed that MALDI-TOF MS method allowed the
identification of 11 isolates with a score > 2.0, indicating genus
and species identification with certainty. They were identified
in three different species: C. albicans (C1, C2, HE3, HE4, HE5, HE6
and HE7 isolates), C. glabrata (F1, F2 and HE10 isolates) and C.
tropicalis (HE2 isolate) (Table 1). MALDI-TOF MS identification of
all the C. albicans and C. tropicalis isolates agrees with the results
obtained with CHROMagar Candida R© medium.
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In vitro anti-Candida activity of lactobacilli
Antimicrobial activity of Lactobacillus strains
Twelve Lactobacillus strains (40%) were able to inhibit the growth
of at least one Candida spp. strain (Table 1). The strains identi-
fied as C. albicans were inhibited by a higher number of lacto-
bacilli compared to C. glabrata and C. tropicalis strains. Growth
inhibition zones (ranging from 1.33 ± 0.33 to 13.66 ± 3.29 mm
diameter) were evidenced in most of C. albicans strains, while
C. glabrata and C. tropicalis strains were inhibited only in the
area above the lactobacilli colony (Table 1). 91.66% of lacto-
bacilli showing anti-Candida activity were isolated from healthy
vagina, out of which 5, 3 and 3 were obligate homofermenta-
tive, facultative and obligate heterofermentative strains, respec-
tively. All these strains proved to be moderate or strong hydro-
gen peroxide producers. Moreover, 63.63% (L. gasseri CRL1320
and CRL1322, L. salivarius CRL1296, L. paracasei CRL1512, L. rham-
nosus CRL1332 and CRL1511, and L. mucosae CRL1508) reached
final pH values between 4.00 to 4.35 after growth in MRS broth,
each of them being able to inhibit seven to eleven Candida spp.
strains. The remaining 36.37% lactobacilli (L. gasseri CRL1261 and
CRL1263, and L. reuteri CRL1324 and 1327) reached higher pH val-
ues (between 4.36 and 4.71) and inhibited a lower number of
Candida strains (2 to 6 isolates). L. salivarius CRL1328, an obli-
gate homofermentative bacterium and non-hydrogen peroxide-
producing Lactobacillus, was the only strain with anti-Candida
activity originally isolated from an unhealthy vagina (with sign
of mycoses and vaginosis). This strain reached pH 4.04 after
growth in MRS broth and was able to inhibit eight Candida strains
(Table 1).
Although low pH values in Lactobacillus cultures were associ-
ated with a higher number of inhibited Candida strains, seven-
teen homofermentative Lactobacillus strains (56.66%) produced
low pH values with no inhibitory effect on the fungi. This result
suggests that organic acid is not the only factor responsible for
the inhibitory effect.
On the other hand, a strain-dependent inhibitory effect was
evidenced in L. gasseri and L. rhamnosus species. Only four out
of the sixteen L. gasseri strains showed anti-Candida activity, L.
gasseri CRL1320 being the only strain able to inhibit 100% of
fungus strains, while L. gasseri CRL1261, CRL1263 and CRL1322
showed inhibition on 5 (45.45%), 2 (18.18%) and 8 (72.72%) Can-
dida, respectively. In addition, the behavior in the L. rhamno-
sus strains was different with respect to anti-Candida activity.
L. rhamnosus CRL1332 inhibited all Candida strains with wider
inhibition zones (from 9.00 ± 1.63 to 13.66 ± 3.29 mm diameter)
compared to L. rhamnosus CRL1511 (72.72% inhibited Candida and
3.00 ± 1.53 to 6.33 ± 0.88 mm halos). In contrast, a similar anti-
Candida activity was evidenced in two L. salivarius strains and in
two L. reuteri strains evaluated, which inhibited 8 (72.72%) and 6
(54.54%) Candida strains, respectively (Table 1).
Antimicrobial activity of Lactobacillus CFS
When evaluating the effect of Lactobacillus CFS on Candida spp.
growth using the solid medium assay, anti-Candida activity was
not evidenced. However, when the liquid medium assay was
used, thirty CFS (100%) were able to significantly inhibit (P < 0.01)
the growth of at least one of the Candida strains assayed (Fig. 2A).
In agreement with the previously described antimicrobial activ-
ity of lactobacilli, C. albicans strains were more sensitive to Lac-
tobacillus CFS compared to C. glabrata and C. tropicalis strains
(Fig. 2A and B). Twenty-one (70%) and nine (30%) CSF were
obtained from lactobacilli isolated from healthy and unhealthy
vaginas, respectively (Fig. S1, Supporting Information). Most of
them (22 CFS) were from homofermentative lactobacilli, either
moderate or strong hydrogen peroxide-producing strains. Also,
18 out of the 22 CFS and L. salivarius CRL1328 CFS (non H2O2 -
producer) showed low pH (between 4.00 and 4.35), being able
to inhibit between 7 and 11 Candida strains (Fig. 2A; Fig. S1,
Supporting Information). Similar results were observed with
3 CSF assayed from facultative heterofermentative lactobacilli
and with 1 of 4 CFS from obligate heterofermentative lactobacilli
(Fig. 2A; Fig. S1, Supporting Information).
Taking into account the differences in Candida growth
(OD630nm values between 1.67 to 2.14, Fig. 2A), the inhibition
rates induced by Lactobacillus CFS were compared to determine
the degree of inhibitory activity and Candida sensitivity (Fig. 2B).
In the same way as in the agar overlay technique, a strain-
dependent inhibitory effect was evidenced with CFS from L.
gasseri, L. rhamnosus and L. jensenni species, while in the case of
CFS from L. reuteri and L. salivarius a similar activity was observed
in CFS from the same species (Fig. 2B).
The CSF showing higher and similar anti-Candida activ-
ity (growth inhibition between 35.70% and 41.32%) were from
8 homofermentative lactobacilli (L. gasseri CRL1252, CRL1255,
CRL1270 and CRL1322, L. jensenii CRL1317, L. johnsonii CRL1292
and L. salivarius CRL1296 and CRL1328) and from two facultative
heterofermentative (L. paracasei CRL1512 and L. rhamnosus CRL
1332) (Fig. 2B). In contrast, the CFS with the lowest activity (inhi-
bition lower than 20%) were from three homofermentative (L.
gasseri CRL1263, CRL1290 and CRL1311) and from four obligate
heterofermentative lactobacilli (L. fermentum CRL1287, L. reuteri
CRL1324 and CRL1327 and L. mucosae CRL1508) (Fig. 2B).
On the other hand, considering that the highest inhibitory
effect was observed in CFS with lower pH (between 4.00 and
4.35), MRS broth adjusted to pH 4.0 with HCl (MRS-HCl) was
assayed in order to determine if low pH contributed to fungus
inhibition. MRS-HCl significantly (P < 0.01) decreased the growth
of all Candida strains, with the exception of C. albicans HE5 and C.
tropicalis HE2, compared with control MRS (Fig. 2A). Additionally,
while MRS-HCl inhibited approximately 21.35% Candida growth,
19 out of 30 CFS induced a higher and significant (P < 0.01)
inhibition (between 28.68 and 41.32%) compared with MRS-HCl
(Fig. 2B). On the other hand, the results of NaOH-neutralized
CFS treated with catalase against C. albicans C2 showed that the
inhibitory effect of 29 Lactobacillus CFS (96.66%) was significantly
reduced (P < 0.01) with NaOH treatment, suggesting that the
antagonistic effect was produced by organic acids released in
CSF. Also, the CFS anti-Candida activity from L. gasseri CRL1320,
L. jensenii CRL1333 and L. reuteri CRL1324 and CRL1327 showed
a significantly higher reduction (P < 0.05) after NaOH-catalase
treatment, indicating that H2O2 can cooperates in the inhibitory
effect against C. albicans C2 (Fig. 3).
When comparing the sensitivity of Candida spp. to Lactobacil-
lus CFS, significant differences (P < 0.05) between the C. albi-
cans strains were obtained. C2 and HE6 strains showed a similar
pattern and were the most strongly inhibited strains (approxi-
mately with 40% growth inhibition). The average growth inhibi-
tion of C. albicans HE3, HE5 and HE7 strains was 36.13% ± 0.64%
while against C1 and HE4 strains it was 30.64% ± 1.32% The
three C. glabrata strains showed a similar behavior in the pres-
ence of Lactobacillus CFS, with an average growth inhibition of
13.49% ± 0.31% In a similar way, C. tropicalis HE2 growth was
inhibited in the presence of CFS by 16.78% ± 0.45% Fig. 2B).
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Figure 2. Growth inhibition of vaginal clinical isolates of Candida spp. by Lactobacillus CFS. (A) Inhibitory effects of CFS from vaginal lactobacilli on Candida spp. growth
in SD broth after 24 h of incubation. Data are plotted as mean values of OD at 630 nm ± standard error from three independent experiments. ∗indicates statistically
significant differences (P < 0.01) compared to the control using Tukey’s test. (B) Main effect of Lactobacillus CFS and Candida strains on growth inhibition rate (%)
[(ODcontrol—ODCFS)/ODcontrol x 100)]. In the ‘Lactobacillus CFS’ panel, each point indicates the mean value of the growth inhibition rate induced by each Lactobacillus CFS
in all Candida strains evaluated. In the ‘Candida strains’ panel, each point indicates the mean value of the growth inhibition rate for each Candida strain induced by all
Lactobacillus strains tested. In each panel, different letters indicate statistically significant differences (P < 0.05) between the mean values of the growth inhibition rate
(%) of levels of the factor assayed (Lactobacillus CFS and Candida strains) according to Tukey’s test. L.ga.: L. gasseri; L.je.: L. jensenii; L.jo.: L. johnsonii; L.sa.: L. salivarius;
L.fe.: L. fermentum; L.re.: L. reuteri; L.mu.: L. mucosae; L.pa.: L. paracasei; L.rh.: L. rhamnosus. The numbers after the Lactobacillus strains abbreviation correspond to CRL
number. C.alb.: C. albicans; C.gla.: C. glabatra; C.tro.: C. tropicalis. OHo: obligate homofermentative group; FHe: facultative heterofermentative group; OHe: obligate
heterofermentative group.
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Figure 3. Inhibition of C. albicans C2 growth by different Lactobacillus CFS either untreated, treated with NaOH or NaOH plus catalase. Data are plotted as average values
of growth inhibition rate (%) [(ODcontrol—ODCFS)/ODcontrol x 100)] ± standard error. Statistically significant differences between mean values of growth inhibition rate (%)
obtained with the different CFS treatment are indicated by different letters (P < 0.05).
Anti-Candida activity of lactobacilli in a mice
experimental model
L. reuteri CRL1324 and L. rhamnosus CRL1332 strains were selected
to evaluate the effect of their i.va. administration (in preven-
tive, therapeutic and preventive-therapeutic schemes or proto-
cols) against an i.va. challenge with C. albicans C2 in a murine
experimental model. Even though L. reuteri CRL1324 did not
show high in vitro anti-Candida activity, this strain was selected
supported by previous studies indicating its ability to stimulate
the immune system in the murine vaginal tract (De Gregorio,
Juárez Tomás and Nader-Macı́as 2016). In contrast, L. rhamno-
sus CRL1332 was chosen because of the high in vitro anti-Candida
activity evidenced in this work. On the other hand, the C. albi-
cans C2 strain was used due to its highest sensitivity to vaginal
lactobacilli.
When evaluating the different Lactobacillus protocols against
i.va. C. albicans C2 challenge, the preventive or therapeutic
schemes of L. reuteri CRL 1324 and L. rhamnosus CRL 1332
did not show a protective effect (Fig. 4A). However, the com-
bined preventive-therapeutic treatments of the two Lactobacillus
strains evidenced a significant inhibitory effect (P < 0.05) against
C. albicans C2. L. reuteri CRL1324 induced a significant reduction
in viable cell numbers of C. albicans C2 only at 7 days post-C.a.
challenge when compared to control mice. However, L. rhamno-
sus CRL1332 was able to generate the same type of effect since
day 4 post-C.a. challenge. Furthermore, continuous treatment
with L. rhamnosus CRL1332 showed a complete inhibition of C.
albicans C2 at 7 days post-C.a. challenge (Fig. 4A).
With respect to the number of viable Lactobacillus cells recov-
ered in v.w. of mice under the different protocols, a significantly
higher number (around 1–1.5 log units, p < 0.05) of L. rhamnosus
CRL1332 CFU was observed since day 4 post-C.a. challenge in the
therapeutic and preventive-therapeutic scheme compared with
the preventive scheme. The same results were obtained for L.
reuteri CRL1324, but since 7 days post-C.a. challenge (Fig. 4B). The
viable cell number of L. reuteri CRL1324 and L. rhamnosus CRL1332
recovered in murine v.w. was similar (without significant dif-
ferences) between the therapeutic and preventive-therapeutic
schemes and in the different sampling days (Fig. 4B).
The cytological and histological evaluation of the murine
vaginal tract evidenced that the challenge with C. albicans C2
induced a leukocyte influx in all sampling days (Fig. 5). How-
ever, this influx was reduced with the preventive-therapeutic
treatment of L. reuteri CRL1324 and L. rhamnosus CRL1332 since
days 4 and 7 post-C.a. challenge respectively (Fig. 5A and B). On
the other hand, the preventive and therapeutic treatments of
the two lactobacilli strains did not reduce the leukocyte influx
induced by C. albicans C2 challenge (data not shown).
DISCUSSION
Several studies have suggested that the administration of Lac-
tobacillus strains with beneficial properties can be an effective
strategy for VVC prevention or a supplementary therapy to the
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Figure 4. Effects of preventive, therapeutic or preventive-therapeutic treatments with L. reuteri CRL1324 (CRL1324) or L. rhamnosus CRL1332 (CRL1332) intravaginally
(i.va.) administered against i.va. challenge with C. albicans C2 (C.a.) in a murine experimental model. (A) C.a. viable cells in vaginal washings (v.w.) of mice in the
different experimental groups (control and treatments with Lactobacillus strains) (B) CRL1324 or CRL1332 viable cells in v.w. of mice in the different experimental
groups. Data are plotted as average values of C.a., CRL1324 or CRL1332 viable cell numbers ± standard error. Statistically significant differences between the log CFU
mL−1 mean values of experimental groups on the same day post-C.a. challenge are indicated by different letters: a, b and c (P < 0.05). It means that there are statistically
significant differences when the mean values didn´t share one common letter. Statistically significant differences between the log CFU mL−1 mean values of the same
experimental group on the different days post-C.a. challenge are indicated by the symbol ∗ (P < 0.05).
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Figure 5. Photographs of (A) May Grunwald-Giemsa-stained vaginal smears and (B) Hematoxylin–Eosin-stained vaginal slides from BALB/c mice intravaginally (i.va.)
challenged with C. albicans C2 (C.a.) (control) and mice i.va. inoculated seven times with 108 CFU of L. reuteri CRL1324 (CRL1324) or L. rhamnosus CRL1332 (CRL1332), later
i.va. challenged with 1 × 106 CFU of C.a., and i.va. inoculated seven more times with CRL1324 or CRL1332 (preventive-therapeutic treatment) on different days post-C.a.
challenge. Leucocyte influx in the vaginal wash and lumen of C.a.-challenged mice is indicated with black arrows. Results are representative of three independent
experiments.
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conventional antifungal treatments of this illness (Osset et al.
2001; Reid, Kim and Kohler 2006; Ehrstro et al. 2010; De Seta et al.
2014; Vladareanu et al. 2018). In this way, it should be empha-
sized that different beneficial Lactobacillus strains are able to
express a variety of properties and effects on Candida spp.; thus,
in vitro and experimental animal assays are useful and required
for the selection of the best candidate Lactobacillus strains with
anti-Candida activity (Strus et al. 2005; Ronnqvist et al. 2007; Joo
et al. 2012; Parolin et al. 2015; Wang et al. 2017).
In this work, eleven vaginal clinical isolates of Candida sp.
were identified down to the species level in order to further eval-
uate the antagonistic effect of Lactobacillus strains on the fungi
by in vitro and in vivo studies. The results showed that most of
the strains were identified as C. albicans, and in a lesser num-
ber as C. glabrata and C. tropicalis. Similar results were published
by Vicariotto et al. (2012), who identified twenty-four strains as
C. albicans (80.0%), two as C. glabrata (6.7%), one as C. papapsilosis
(3.3%), one as C. tropicalis (3.3%) and two as other Candida species
(6.7%) out of thirty vaginal clinical isolates. These results are
consistent with those reported in the literature where the eti-
ological agent most frequently responsible for VVC is C. albicans
(Cassone 2015; da Silva Dantas et al. 2016), eventhough this work
was not conceived as an epidemiological study.
When evaluating the in vitro inhibitory effect of thirty Lac-
tobacillus strains against Candida spp., different results were
obtained according to the three methods applied (Table 1 and
Fig. 2). The liquid medium method indicated a higher num-
ber of lactobacilli with anti-Candida activity compared with the
solid overlay method, while the agar plate diffusion method
showed no inhibition of the fungi. In a similar way, Osset et al.
(2001) reported the capability of lactobacilli to inhibit C. albicans
strains growth in liquid, but not in solid culture media. More-
over, Mastromarino et al. (2002) and Juárez Tomás et al. (2011)
showed the inhibition of various urogenital pathogens, but not
of C. albicans strains by the agar plate diffusion method. Other
investigators reported the anti-Candida activity of different vagi-
nal Lactobacillus strains, applying the agar overlay and/or liq-
uid methods (Coman et al. 2015; Parolin et al. 2015; Wang et al.
2017). In the present work, the different results obtained with
the three methods applied could be explained by the physical
state of the media, and the environment where the inhibitory
substances exert their effect, as well as by the concentration of
antimicrobial substances that lactobacilli can produce or secrete
into solid and/or liquid media. In a similar way, Pauli (2006) has
described that the volatilization and amount of substance/s to
evaluate, the agar media type, pH, and the agar volume can all
strongly affect the inhibition zone giving false-positive or neg-
ative results in the agar diffusion method. Also, Scorzoni et al.
(2007) have reported that the microdilution method is more sen-
sitive than the agar diffusion when evaluating the antifungal
activity against Candida spp. of crude extracts, fractions, and
pure substances from different species of the plant families.
Thus, the different inhibitory patterns obtained in this work
highlight the importance of applying more than one method to
evaluate and define the in vitro antimicrobial effect of lactobacilli
when trying to select the most adequate candidate Lactobacillus
strains with anti-Candida activity. This recommendation is also
indicated in the review published by Scorzoni et al. (2016) where
the authors strongly suggest that different in vitro methodol-
ogy must be applied to perform an adequate screening of newly
described antifungals.
The lack of H2O2-producing Lactobacillus species in vagina has
been related to the development of VVC (Vitali et al. 2007). In
this work, out of thirty Lactobacillus strains assayed, twenty-nine
showed to be hydrogen peroxide producers, and inhibit at least
one Candida strain. However, some highly H2O2-producing lacto-
bacilli evidenced low anti-Candida activity compared to moder-
ate producers, and to L. salivarius CRL1328 (non-H2O2-producing
Lactobacillus), suggesting that other antimicrobial substances
can also contribute to the inhibitory effect against the yeast, or
either a synergistic effect of them. Similarly, other authors have
reported that the inhibitory effects of lactobacilli on Candida spp.
is not associated with H2O2 production, and can be attributed to
organic acid production (Strus et al. 2005; Chew et al. 2015). In this
way, lactobacilli reaching a lower pH after growth in MRS broth
were able to inhibit a higher number of Candida strains. Most
of them were homofermentative and facultative heterofermen-
tative lactobacilli, which produce higher lactic acid levels than
the obligate heterofermentative. Thus, by using MRS adjusted
to pH 4 with HCl, it was demonstrated that low pH affected Can-
dida growth (Fig. 2), which was confirmed when most Lactobacil-
lus CFS reduced their antagonistic effect on C. albicans C2 after
the NaOH treatment (Fig. 3).
Previous studies demonstrated that each Candida strain
expresses its own response to antifungals. In general, C. albi-
cans and C. tropicalis species are susceptible to the drugs fre-
quently used for mycosis treatments, while C. glabrata is less
susceptible and C. krusei has intrinsic resistant to fluconazole
(Arendrup 2013). Keeping these differences in mind, the sus-
ceptibility of three Candida species to the antimicrobial effect
of different lactobacilli was evaluated. C. albicans strains were
more sensitive than C. glabrata and C. tropicalis strains (Fig. 2).
In a similar way, Parolin et al. (2015) and do Carmo et al. (2016)
reported that L. gasseri, L. vaginalis, L. crispatus and L. fermen-
tum strains showed a higher inhibitory effect on C. albicans clin-
ical isolates compared with C. non-albicans. The present work
reports the effect of a broad spectrum of vaginal Lactobacillus
species, such as L. jensenii, L. johnsonii, L. salivarius, L. rhamno-
sus and L. reuteri, among others, against Candida spp. associated
with vaginal infections. Thus, the results obtained provide sig-
nificant information on the potential application of vaginal lac-
tobacilli in VVC prevention and treatment, and the importance
of the methodology applied for the selection of the most promis-
ing beneficial strains.
Eventhough L. crispatus species is described as one of the
most abundant species in vagina and crucial for the mainte-
nance of vaginal health (Petrova et al. 2015); this species was
not frequently isolated in our previous studies (Ocaña et al.
1999; Juarez Tomás et al. 2011). Then, the results presented in
this paper cannot be considered as an epidemiological survey,
because was applied only to a low number of vaginal beneficial
Lactobacillus strains to determine their anti-Candida activity. The
final purpose was to select candidate strains to prevent or treat
vaginal candidiasis, in a way to complement previous studies of
our research group.
The use of animal experimental models of vaginal candidi-
asis has generated several reports on the fungal pathogenic
determinants and on the importance of the inflammatory and
immune responses required for the successful control of human
infection (Cassone and Sobel 2016). Animal experimental mod-
els are also a critical element to determine the protective mech-
anisms of Lactobacillus strains, since they provide information
that is not possible to obtain from in vitro studies. In the case
of products containing lactobacilli for human application, pro-
tocols carried out in laboratory animals are essential prior to
phase I, II and III clinical trials (De Gregorio et al. 2012; ISAPP 2013;
De Gregorio et al., 2014, 2015; De Gregorio et al. 2016). However,
to this day, the effect of vaginal lactobacilli on C. albicans in an
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experimental murine model has been scarcely reported. Joo et al.
(2012) demonstrated that a three-day application of Lactobacillus
helveticus HY7801, a species not commonly reported in human
vagina (Human Microbiome Project Consortium 2012; Integra-
tive HMP (iHMP) Research Network Consortium 2014), amelio-
rated VVC in mice by inhibition of fungal growth, expression
of pro-inflammatory cytokines and enzymes, and NF-κB acti-
vation. To the best of our knowledge, the present work is the
first to evaluate and compare the preventive, therapeutic and
preventive-therapeutic effect of vaginal lactobacilli strains (L.
reuteri CRL1324 and L. rhamnosus CRL1332) against i.va C. albicans
challenge in a murine experimental model.
L. reuteri CRL1324 and L. rhamnosus CRL1332 were selected
to conduct in vivo assays with a murine model supported by
previous studies of our research group evidencing that the two
strains have the ability to produce biofilm, a property that could
contribute to interfere with Candida vaginal colonization (Lec-
cese Terraf et al. 2012). Moreover, L. reuteri CRL1324 produced
an immunomodulatory effect on a murine model (De Grego-
rio, Juárez Tomás and Nader-Macı́as 2016), while in this work
L. rhamnosus CRL1332 have demonstrated a strong in vitro anti-
Candida activity. Different authors have shown that the anti-
Candida mechanisms exerted by Lactobacillus species include
restoration of normal vaginal microbiota, interference with Can-
dida colonization, inhibition of growth and biofilm formation of
Candida spp. and immunomodulation in the host (Reid, Kim and
Kohler 2006; Wagner and Johnson 2012; Parolin et al. 2015; San-
tos et al. 2016; Niu et al. 2017). Some of these mechanisms are
associated with the beneficial properties of the two lactic strains
selected for in vivo assays.
C. albicans is an opportunistic pathogen with the ability to
adhere to, invade, and induce cell damage in the vaginal mucosa.
The stimulation of mucosal immunity can induce certain signs
and symptoms of the disease or their absence (Sobel 2007; Rast
et al. 2016). In this work, the vaginal tract of mice i.va. challenged
with C. albicans C2 was successfully colonized, inducing a high
leukocyte influx to the mucosa on all sampling days. However,
the decrease in Candida colonization and leukocyte influx was
only evidenced with the i.va. preventive-therapeutic adminis-
tration of L. reuteri CRL1324 or L. rhamonosus CRL1332 strains
(Fig. 4 and 5), while the preventive or therapeutic administra-
tions alone showed no effect. In a similar way, some researchers
have demonstrated that the prolonged repetitive administration
of vaginal tablets containing L. fermentum LF10 and L. acidophilus
LA02 was able to significantly solve Candida yeast symptoms and
prevent VVC recurrence in women (Vicariotto et al. 2012; Murina
et al. 2014).
When evaluating Lactobacillus colonization in murine v.w., a
significantly higher number of L. reuteri CRL1324 and L. rhamno-
sus CRL1332 was observed at day 7 after Candida challenge in the
preventive-therapeutic lactobacilli protocol, only comparable to
the preventive one. These results suggest that the number of
viable Lactobacillus cells was not directly related to the inhibitory
effect. Our hypothesis is that the prolonged vaginal administra-
tion of lactobacilli could: a) generate a barrier or biofilm able to
interfere with Candida colonization; b) induce a higher accumu-
lation of antimicrobial substances such as lactic acid or c) mod-
ulate the local immune response.
When comparing the effect of the preventive-therapeutic
treatment between Lactobacillus strains, L. rhamnosus CRL1332
showed a higher inhibition of C. albicans C2 vaginal coloniza-
tion, while L. reuteri CRL1324 reduced more quickly the leukocyte
influx induced by the yeast (Fig. 4A and Fig. 5A and B). Consider-
ing these results and the properties of the strains, one possibil-
ity is that the inhibitory effect of L. rhamnosus CRL1332 could be
related to organic acids production and the consequent pH low-
ering, while the effect of L. reuteri CRL1324 could be more closely
related to the modulation of the immune system. Further stud-
ies are required to demonstrate the mechanisms involved in the
inhibition of C. albicans by these lactobacilli.
In conclusion, human vaginal lactobacilli exhibited in vitro
antimicrobial effects on Candida spp. By employing a murine
experimental model, the preventive-therapeutic administration
of either L. reuteri CRL1324 or L. rhamnosus CRL1332 induced a
decrease in C. albicans vaginal colonization as well as in the
inflammatory response produced by the yeast. Therefore, L.
reuteri CRL1324 and L. rhamnosus CRL1332 could be considered
as new biological agents capable of reducing VVC.
ACKNOWLEDGEMENTS
We wish to thank Dr. Virginia Ocaña, Dr. Cristina Gaudioso de
Allori and Cecilia Vallejo for kindly supplying Candida strains. We
are also grateful for the helpful cooperation of Dr. Silvina Juárez
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